p70S6K (ribosomal protein S6 kinase 1, p70S6K1, S6K1, encoded by RPS6KB1) — the serine/threonine protein kinase functioning as a key downstream effector of the mTOR complex 1 (mTORC1) signaling pathway, phosphorylating ribosomal protein S6 and eIF4B to stimulate translational initiation and ribosome biogenesis, regulating cell growth, protein synthesis, cell cycle progression, and glucose metabolism — representing the molecular biology research target and therapeutic development focus of the 70 kDa Ribosomal Protein S6 Kinase Market, with S6K1 research reagents, inhibitors, and antibodies enabling the academic and pharmaceutical investigation of this kinase's role in cancer, metabolic disease, aging, and neurological disorders.

The mTORC1-p70S6K1 signaling axis — the biological rationale for therapeutic interest — the canonical signaling pathway: upstream growth factors (insulin, IGF-1, EGF, VEGF) activating receptor tyrosine kinases → PI3K → AKT → TSC1/2 inhibition → Rheb GTPase activation → mTORC1 activation → p70S6K1 phosphorylation (Thr389 by mTORC1; Thr229 by PDK1) → S6K1 activation → ribosomal protein S6 phosphorylation → protein synthesis and cell growth. The pathway's central integration of nutrient, energy, and growth factor signals with the cellular translation machinery making S6K1 a sensor and effector of metabolic state with direct implications for cancer cell proliferation (where mTORC1-S6K1 is constitutively activated), insulin resistance (S6K1-mediated negative feedback on IRS-1), aging (S6K1 deletion extending lifespan in mice — Lin et al. 2015), and tuberous sclerosis complex (TSC1/2 mutation causing mTORC1-S6K1 hyperactivation).

S6K1 cancer biology — the therapeutic target rationale — the RPS6KB1 gene (encoding S6K1) located at chromosome 17q23 — a region frequently amplified in human breast cancer (twenty to thirty percent of luminal B breast cancers), ovarian cancer, and other epithelial malignancies — with S6K1 overexpression and amplification correlating with poor prognosis, tamoxifen resistance (in ER+ breast cancer), and trastuzumab resistance (in HER2+ breast cancer). The therapeutic logic: mTOR inhibitors (rapalogs — everolimus/Afinitor, temsirolimus/Torisel) reducing S6K1 phosphorylation and activity in cancer cells — validating the mTORC1-S6K1 axis as a pharmacological target in oncology. However, a critical feedback loop: S6K1 phosphorylates and degrades IRS-1 (the insulin receptor substrate), creating negative feedback on PI3K-AKT signaling — meaning mTOR inhibition reduces S6K1 activity and thus relieves IRS-1 degradation, enabling AKT reactivation through upstream pathway de-repression — a resistance mechanism explaining the limited efficacy of rapalogs as single agents.

p70S6K research tools — the market-enabling products — the scientific investigation of S6K1 biology requiring: phospho-specific antibodies (anti-phospho-Thr389-S6K1 and anti-phospho-S235/S236-S6 — Cell Signaling Technology catalog dominance in this space); recombinant S6K1 kinase enzymes (active and kinase-dead mutants) for in vitro kinase assays and drug screening; S6K1 ELISA kits quantifying total and phosphorylated S6K1 from cell lysates; S6K1 siRNA and shRNA constructs for knockdown studies; S6K1 overexpression plasmids (wild-type and constitutively active S371D/E mutant); and selective p70S6K inhibitors (PF-4708671 — Pfizer; A77-1726; BI-D1870) enabling mechanistic studies of S6K1-specific (versus mTOR-broad) pathway functions.

Do you think the development of selective p70S6K1 inhibitors will eventually demonstrate superior clinical efficacy versus mTOR inhibitors (rapalogs) in cancers with S6K1 amplification or overexpression — by avoiding the feedback AKT reactivation that limits rapalog efficacy — creating a viable clinical development program for S6K1 as a standalone therapeutic target in oncology?

FAQ

What are the major research tools used to study p70S6K1 activity and what are their applications? p70S6K1 research tools: antibodies: phospho-specific antibodies: anti-phospho-T389-S6K1 (CST #9234, #9206): mTORC1 phosphorylation site; western blot, IHC, flow cytometry; gold standard for mTORC1 activity readout; anti-phospho-T229-S6K1 (CST #9338): PDK1 phosphorylation site; total S6K1 antibodies: anti-S6K1 (CST #2708; Abcam ab32359): detecting total protein; loading control; S6 downstream readout: anti-phospho-S235/S236-S6 (CST #4856): direct S6K1 substrate; most used surrogate for S6K1 activity; inhibitors (research-grade): PF-4708671 (Selleckchem S2683; Abcam ab146544): selective S6K1 inhibitor; IC50 S6K1: twenty nanomolar; selectivity: one hundred-plus fold vs S6K2; used in cell culture and animal studies; A77-1726: alternative S6K1 inhibitor; BI-D1870 (Cayman Chemical): RSK family inhibitor; less selective than PF-4708671; kinase assay tools: recombinant active S6K1: ProQinase, SignalChem, Thermo Fisher; for in vitro kinase assay; substrate: recombinant S6 protein (substrate); radioactive ATP (³²P-γATP): measuring substrate phosphorylation; ADP-Glo assay (Promega): non-radioactive kinase activity measurement; luminescence readout; molecular biology tools: siRNA: Dharmacon siRNA S6K1 SMARTpool; Qiagen validated siRNA; shRNA: Addgene S6K1 shRNA plasmids; validated knockdown; overexpression: pRK5-S6K1 (wild type, constitutively active T389E); CRISPR: S6K1 knockout cell lines; characterization; reporter constructs: S6K1 FRET biosensors; real-time S6K1 activity in live cells; flow cytometry: PhosFlow S6K1: intracellular staining for phospho-S6K1; high-throughput screening applications.

How does p70S6K1 contribute to insulin resistance and metabolic disease pathology? S6K1 in insulin resistance and metabolic disease: S6K1 negative feedback mechanism: physiological: after insulin → mTORC1 activation → S6K1 activation → S6K1 phosphorylates IRS-1 at Ser307, Ser312, Ser632 (inhibitory sites) → IRS-1 degradation → reduced PI3K-AKT signaling; function: negative feedback limiting insulin signal duration; pathological: chronic over-nutrition → persistent mTORC1-S6K1 activation → chronic IRS-1 inhibitory phosphorylation → insulin resistance; obesity and S6K1: adipose tissue: S6K1 activated in obesity; IRS-1 Ser307 chronically phosphorylated; glucose uptake impaired; skeletal muscle: S6K1-mediated IRS-1 degradation reducing GLUT4 translocation; glucose utilization impaired; liver: S6K1 promoting hepatic gluconeogenesis; contributing to fasting hyperglycemia; S6K1 genetic evidence: S6K1 knockout mice (Le Bacquer 2007 — Developmental Cell): protected from diet-induced obesity; improved insulin sensitivity; reduced adiposity; life extension (Selman et al. 2009 — Science: females, approx. nineteen percent); human data: RPS6KB1 polymorphisms associated with body mass index and insulin sensitivity (GWAS data); therapeutic implications: S6K1 inhibition — potentially improving insulin sensitivity in type 2 diabetes; preclinical evidence: PF-4708671 improving insulin sensitivity in obese rodents; challenge: S6K1 role in beta cell function — S6K1 regulating beta cell mass and insulin secretion; complete S6K1 inhibition potentially impairing insulin secretion; therapeutic window narrow; mTOR-S6K1 in aging: caloric restriction → reduced mTOR-S6K1 activity → lifespan extension (worm, fly, mouse, yeast); rapamycin extending lifespan in mice (Harrison 2009 — Nature); mechanism: partly through S6K1 inhibition; S6K1 deletion — lifespan extension independent of rapamycin; targeting S6K1 for healthy aging: preclinical rationale; human translation pending.

#p70S6K #70kDaRibosomalProteinS6KinaseMarket #mTORpathway #S6Kinase #mTORinhibitors